Rubius Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Laurence A. Turka
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 399 Binney Street Cambridge MA United States of America 02139
- IPO Date
- Jul 18, 2018
- CIK
- 0001709401
- Website
- rubiustx.com
- Similar Companies
- Business
- Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of cellular medicines known as Red Cell Therapeutics™ (RCTs) for the treatment of cancer, autoimmune diseases, and rare diseases. Founded in 2013 and headquartered in Foxborough, Massachusetts, the company leverages its proprietary RED PLATFORM™ to genetically engineer and culture red blood cells that are designed to be selective, potent, and ready-to-use cellular therapies. Rubius’s main products include RCTs engineered to express biotherapeutic proteins either within or on the surface of red cells, enabling treatment modalities that activate immune responses such as potent cell-cell interactions and immune tolerance induction across therapeutic areas including oncology and autoimmunity. Its pipeline has featured candidates like RTX-240 and RTX-224, which were investigated in clinical trials for advanced solid tumors, including non-small cell lung cancer, renal cell carcinoma, melanoma, and triple-negative breast cancer. In recent major changes, Rubius Therapeutics announced a strategic restructuring in 2022 to focus on advancing a next-generation red blood cell-based cell conjugation platform, shifting away from earlier clinical trials of RTX-240 and RTX-224 due to promising technical progress with the new platform that offers enhanced versatility, efficacy, and cost efficiency. This restructuring involved discontinuing ongoing Phase 1 clinical trials of prior candidates, implementing significant workforce reductions, and exploring operational cost-saving measures including a potential sale of its manufacturing facility in Rhode Island. Despite these changes, the company continues robust preclinical research and technical development to advance its next-generation RCT platform with the goal of creating more effective and versatile cellular therapies. Rubius operates primarily in the United States but targets global markets through its innovative cellular therapeutic approach. The company focuses on a biopharmaceutical industry segment concerned with cutting-edge cellular therapies and immune system modulation. Rubius targets oncology and autoimmune patients through allogeneic red blood cell therapeutics designed to activate and regulate immune responses. Its proprietary RED PLATFORM™ distinguishes Rubius as a pioneer in red blood cell therapeutics. The company was originally known as VL26, Inc. before changing its name to Rubius Therapeutics, Inc. Its operations have included clinical trial activity and advanced manufacturing capabilities in Cambridge, Massachusetts, and Rhode Island. Rubius was recognized among top workplaces regionally but has faced operational challenges leading to its recent pivot and restructuring efforts focused on next-generation therapeutic platforms. Overall, Rubius Therapeutics presents a transformative approach to biopharmaceuticals by developing engineered red blood cell therapies with broad potential applications in treating cancer, autoimmune diseases, and other conditions, driven by innovation in cell conjugation technologies and ongoing strategic realignment for sustained advancement in cellular medicine development.
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
Why Is Rubius Therapeutics (RUBY) Stock Down 16% Today?
Hot Penny Stocks to Buy This Week? 3 to Watch Now
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
3 High Volume Penny Stocks To Watch Before Next Week
Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?
Rubius: Poor Data, Punishing Environment, Beaten Stock
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
Here Are 3 Penny Stocks You Need to Know About in May 2022
Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
RUBY PIPELINE FILES TO REORGANIZE UNDER CHAPTER 11 OF THE BANKRUPTCY CODE
Rubius Looks Attractive Before AACR Data Readout
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
Rubius Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?